Industry Overview

Asia-Pacific CDMO market was valued at $87.0 billion in 2025 and is projected to reach $170.5 billion by 2035, growing at a CAGR of 7.0% during the forecast period (2026–2035). The Asia-Pacific healthcare contract development and manufacturing organization market is experiencing significant growth, driven by increasing pharmaceutical production and rising demand for cost-effective outsourcing solutions. Expansion of the biotechnology sector and a growing number of emerging pharmaceutical companies are fueling the need for specialized development and manufacturing services. Government incentives, favorable regulatory reforms, and supportive infrastructure in countries like India and China are further enhancing market attractiveness. Adoption of advanced manufacturing technologies and process automation is improving efficiency and scalability. Strategic collaborations with global pharmaceutical firms are also contributing to market expansion. Collectively, these factors are supporting sustained growth in the region throughout the forecast period.

Market Dynamics

Rising Demand for Biologics and Advanced Therapies

The global CDMO market is witnessing strong growth driven by increasing demand for biologics, cell and gene therapies, and complex drug formulations. Pharmaceutical companies are outsourcing development and manufacturing to specialized CDMOs to access advanced technical expertise and reduce time-to-market. Investment in high-containment facilities, single-use systems, and analytical capabilities is expanding rapidly. Key players are enhancing service portfolios to support end-to-end solutions from development to commercial production. Regulatory compliance and quality assurance remain critical focus areas. This trend is reinforcing the strategic importance of CDMOs in the global pharmaceutical ecosystem.

Expansion of Strategic Partnerships and Integrated Services

Pharmaceutical and biotechnology companies are increasingly entering long-term collaborations with CDMOs to ensure reliable supply and operational efficiency. Integrated service offerings combining development, analytical support, and large-scale manufacturing are gaining preference. This approach helps reduce operational risk and accelerates product commercialization. Major CDMOs are investing in digital tools, process automation, and facility modernization to strengthen client relationships. Long-term agreements and strategic alliances are shaping the competitive landscape. These developments are driving global market growth and fostering innovation across the sector.

Market Segmentation

• Based on the services, the market is segmented into contract development and contract manufacturing.

Contract Manufacturing Segment to Lead the Market with the Largest Share

Contract manufacturing is the leading sub-segment in the global CDMO market, driven by growing demand for large-scale production of small molecules, biologics, and complex drug formulations. Pharmaceutical and biotechnology companies increasingly outsource manufacturing to optimize costs, expand capacity, and maintain regulatory compliance. Leading CDMOs offer advanced facilities, high-containment systems, and expertise in sterile injectables and high-potency APIs. Recent trends include the adoption of continuous manufacturing, single-use technologies, and facility expansions to support global supply chains. Strategic partnerships with pharmaceutical innovators are strengthening the market position. The segment continues to dominate due to its critical role in ensuring reliable and scalable production.

Contract Development: A Key Segment in Market Growth

Contract development services are expanding steadily as companies seek specialized support for early and mid-stage drug development. Growth is fueled by demand for formulation design, process optimization, analytical testing, and regulatory support. CDMOs with integrated development capabilities are increasingly preferred, particularly for biologics, complex molecules, and high-value therapies. Recent trends highlight investment in digital modeling, quality-by-design approaches, and scalable process development. The segment enables companies to reduce technical risks before commercialization. Contract development is becoming a strategic growth driver as outsourcing needs evolve globally.

Regional Outlook

The Asia-Pacific CDMO market is further divided by countries, including China, Japan, South Korea, India, Australia & New Zealand, ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, and others), and the Rest of Asia-Pacific.

China Dominates the Market with a Major Share

China is the leading country in the Asia-Pacific CDMO market, supported by its rapidly growing pharmaceutical and biotechnology sectors. The country has become a preferred outsourcing destination due to cost-effective manufacturing, well-established infrastructure, and increasing regulatory alignment with international standards. Growth is driven by rising demand for biologics, generic drugs, and complex formulations, as both domestic and global companies expand production capabilities. Key players are investing in state-of-the-art facilities, single-use technologies, and high-containment systems to support advanced therapies. Strategic collaborations with multinational pharmaceutical firms are also on the rise. These factors collectively position China as the dominant hub for CDMO activities in the region.

Market Players Outlook

The major companies operating in the Asia-Pacific CDMO market include Lonza Group AG, Thermo Fisher Scientific Inc., Samsung Biologics Co., Ltd., WuXi Biologics Co., Ltd., and Akums Drugs and Pharmaceuticals Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In October 2024, Teijin Limited and Hilleman Laboratories, a biotechnology company based in Singapore, announced the signing of a Memorandum of Understanding for the establishment of a strategic international business partnership. The goal of this partnership is to promote the expansion of contract development and manufacturing organization (CDMO) business in the field of cell and gene therapy.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the Asia-Pacific CDMO market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.